Loading
institutionsInstitution
Centro Nacional de Investigaciones Oncológicas (CNIO)
Spain's national cancer research centre, founded by RAS pioneer Mariano Barbacid and known for oncogene, telomere and senescence biology.
Also called: Spanish National Cancer Research CentreCNIO
Overview
The CNIO was created in 1998 with Mariano Barbacid, who had isolated the first human oncogene (HRAS) in 1982, as founding director; María Blasco (telomeres and telomerase) directed it from 2011 to 2025. Its groups made foundational contributions to KRAS-driven pancreatic and lung cancer models, cellular senescence (Manuel Serrano), replication stress (Óscar Fernández-Capetillo), melanoma metastasis (Marisol Soengas) and structural biology, and its Experimental Therapeutics Programme discovers small molecules for academic and industry partners. Clinical research units embedded in Madrid hospitals, including the H12O-CNIO lung unit and breast and prostate units, translate discoveries into trials. The centre runs a familial cancer clinical unit and a large biobank.
Location
Madrid, ES
Type
research institute
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#137 · 34 points (0 Newsweek + 0 NCI + 34 from 17 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Spanish National Cancer Research Centre, including child institutions. 201 works · 3,539 citations · 75% open access · 6% clinical trials · 1% reviews.
Oncology works per year
362022
572023
382024
442025
262026
Most works
- Núria Malats20 works
- Luis G Paz-Ares18 works
- Luis Álvarez‐Vallina14 works
- Joaquín Martínez‐López12 works
- Francisco X. Real12 works
- Evangelina López de Maturana11 works
- Sergio Sabroso‐Lasa11 works
- Fátima Al‐Shahrour10 works
- Óscar Fernández-Capetillo9 works
- Bruno Sáinz9 works
Most cited
- Molecular oncology (RAS, telomeres, senescence)
- Experimental Therapeutics Programme
- Clinical research units in Madrid hospitals
- Familial cancer unit
- Structural biology
Similar pages
- IdeaA synthetic lethality map for every cancer driver in every tissue context
Shares Patient-derived xenografts, CRISPR functional genomics, The undruggable drivers, TP53.
- IdeaMake bespoke mouse cancer models in weeks with in vivo gene editing
Shares Patient-derived xenografts, CRISPR functional genomics, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- CompanyQuanta Therapeutics
Shares KRAS & RAS inhibitors, The undruggable drivers, KRAS, Pancreatic ductal adenocarcinoma.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares The undruggable drivers, TP53, KRAS, Pancreatic ductal adenocarcinoma.
- CompanyKumquat Biosciences
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- TrialKRYSTAL-12
Shares KRAS & RAS inhibitors, The undruggable drivers, KRAS, Non-small-cell lung cancer.
- IdeaAn open degrader consortium against every undruggable driver transcription factor
Shares AI-driven drug & target discovery, The undruggable drivers, TP53, KRAS.
- CompanyFrontier Medicines
Shares KRAS & RAS inhibitors, The undruggable drivers, KRAS, Pancreatic ductal adenocarcinoma.